On top of your game Reg,
As Silviu pointed out to me at the last AGM, Mesoblast are having ongoing discussions with the FDA - it is a bureaucracy but with VERY Pragmatic NEW leadership.
Rexlemestrocel-L is in development for advancedchronic heart failure and chronic low back pain. Two products have beencommercialized in Japan and Europe by Mesoblast’s licensees, and the Companyhas established commercial partnerships in Europe and China for certain Phase 3assets, this tells me that it's only a matter of time for MSB to achieve the FDA outcomes we all believe in.
@ddwn closing posts : "Onwards & Upwards"
ST
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-504
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
-0.025(2.23%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.16 | $1.04 | $14.57M | 13.49M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 21024 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 241 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |